TITLE

At 'Threshold,' Ziopharm's Bid In Sarcoma Fails; Refocus Due

AUTHOR(S)
Osborne, Randy
PUB. DATE
March 2013
SOURCE
BioWorld Today;3/27/2013, Vol. 24 Issue 58, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Ziopharm Oncology Incorporated's Phase III trial with the alkylating agent palifosfamide for first-line, metastatic soft tissue sarcoma failed to meet the primary endpoint of progression-free survival (PFS) but the company will continue to follow the overall survival (OS) rates of patients. According to the author, palifosfamide is still in a Phase III trial called MATISSE for first-line metastatic small-cell lung cancer.
ACCESSION #
86442002

 

Related Articles

  • 'Doxo' Going to Like This One: Ziopharm's Phase II Wins Big. Osborne, Randy // BioWorld Today;11/9/2009, Vol. 20 Issue 216, p1 

    This article reports on the positive results of the Phase II trial of palifosfamide for soft-tissue sarcoma conducted by Ziopharm Oncology Inc. in 2009. The positive results caused the company's stock to grow and strengthen its partnering negotiations. Ziopharm stopped the trial after hitting...

  • ZIOPHARM Oncology Announces Promising Data from Phase 1b Study of Palifosfamide in Small Cell Lung and Other Cancers at AACR-NCI-EORTC Meeting.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p845 

    The article announces that New York-based biopharmaceutical company Ziopharm Oncology Inc. presented promising data from Phase 1b study of intravenous (IV) palifosfamide in small cell lung cancer (SCLC) and other selected cancers at the AACR-NCI-EORTC International Conference on Molecular...

  • Untitled.  // BioWorld Today;6/2/2009, Vol. 20 Issue 104, p12 

    The article reports on the results of Malvern, Pennsylvania-based Gemin X Pharmaceuticals Incorporated's Phase Ib trial of obatoclax (GX15-070), a small-molecule Bcl-2 inhibitor, in first-line patients with extensive-stage small-cell lung cancer. The study revealed that obatoclax can enhance the...

  • ImmunoGen Inc Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate.  // Biomedical Market Newsletter;4/1/2012, Vol. 21, p1 

    The article provides information on the announcement made by ImmunoGen Inc. regarding the initiation of Phase II testing of its IMGN901 product candidate for first-line treatment of small-cell lung cancer (SCLC). The trial is designed to analyze the meaningfully impacts duration of...

  • Synta Announces Presentation of Results of Ganetespib Study in Combination with Docetaxel in Solid Tumors.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p660 

    The article mentions the presentation of Synta Pharmaceuticals Corp.'s results of a study of ganetespib in combination with docetaxel in solid tumors at the meeting of the European Society of Medical Oncology in Stockholm, Sweden. The results show that ganetespib is tolerated when combined with...

  • Ziopharm Phase II Trial Reaches Goal Early.  // Bioworld Week;10/19/2009, Vol. 17 Issue 42, p5 

    The article reports on the end of the randomized Phase II trial of Zymafos, a sarcoma drug candidate from Ziopharm Oncology Inc. in New York. It notes that Ziopharm decided to end the study due to the unexpected efficacy and safety results of the said drug which is later than they expected. With...

  • Pemetrexed: A Review of its Use in the Management of Advanced Non-Squamous Non-Small Cell Lung Cancer. Baldwin, Claudine M.; Perry, Caroline M. // Drugs;2009, Vol. 69 Issue 16, p2279 

    Pemetrexed (Alimta®) is a multi-targeted antifolate cytotoxic agent available for use in the treatment of adults with advanced non-squamous non-small cell lung cancer (NSCLC). It is indicated as initial therapy in combination with cisplatin, as monotherapy after prior chemotherapy, and as...

  • Synta Raises $52M In Offering to Fund Ganetespib’s Phase III. Osborne, Randy // BioWorld Today;11/14/2013, Vol. 24 Issue 220, p1 

    The article reports on the 52.2 million U.S. dollar fund raised by Synta Pharmaceuticals Corp. from a public offering for its effort to expand the Phase III clinical drug trial of the heat-shock protein 90 inhibitor, ganetespib, for treatment of non-small-cell lung cancer (NSCLC), in November...

  • Millennium Pharmaceuticals: more Velcade ventures.  // PharmaWatch: Biotechnology;Apr2006, Vol. 5 Issue 4, p5 

    The article reports on the launch of a phase II trial of Velcade in combination with pemetrexed in non-small lung cancer (NSCLC) initiated by Millennium Pharmaceuticals Inc. and Johnson & Johnson in 2006. The trial will study the effects of Velcade in patients with NSCLC who have failed prior...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics